Key Highlights
- The private equity acquisition of Hologic closed on April 7, 2026, with Blackstone and TPG paying up to $79 per share.
- Shareholders got $76 cash upfront plus contingent value rights potentially worth $3 more based on Breast Health division performance.
- Abu Dhabi Investment Authority and GIC provided minority backing to the transaction.
- CEO Stephen MacMillan stepped down after leading the company for over 12 years; Joe Almeida took over the role.
- Trading in HOLX shares ended, with the stock set for removal from the Nasdaq exchange.
The women’s health technology company Hologic transitioned to private ownership on April 7, 2026, as Blackstone and TPG finalized their buyout valued at as much as $79 for each outstanding share.
Initially unveiled on October 21, 2025, the acquisition gained shareholder backing on February 5, 2026. Investment arms of both the Abu Dhabi Investment Authority and GIC participated as minority stakeholders in the consortium.
Each shareholder collected $76 in immediate cash compensation. Additionally, they obtained a contingent value right that could deliver up to $3 more per share through two separate payments of as much as $1.50 each, contingent upon Hologic achieving specified worldwide revenue benchmarks within its Breast Health segment during fiscal 2026 and 2027.
This CVR arrangement indicates that reaching the maximum $79-per-share valuation depends entirely on hitting those performance targets. For those monitoring the transaction’s ultimate worth, this conditional component merits attention.
Prior to finalization, Hologic documented trailing twelve-month revenue of $4.13 billion, maintained a 60% gross profit margin, and operated with a current ratio exceeding 4. The company carried a market capitalization of $16.97 billion.
Its latest quarterly performance fell beneath analyst projections. The company generated $1.05 billion in revenue versus the anticipated $1.07 billion, while adjusted earnings per share landed at $1.04 compared to the expected $1.09.
Executive Transition
Stephen MacMillan concluded his tenure as CEO upon deal completion, wrapping up more than twelve years leading the organization. Joe Almeida assumed the Chief Executive Officer position effective at closing and was simultaneously appointed as the company’s only board member.
Almeida brings extensive medical technology industry experience. He previously chaired and led Baxter International as President and CEO from 2016 through early 2025, and held identical positions at Covidien before Medtronic’s 2015 acquisition.
This management shift demonstrates the strategic intent of the new ownership groups — Blackstone, overseeing $1.3 trillion in total assets, and TPG, managing $303 billion — to pursue expansion under private equity stewardship.
The deal also restructured Hologic’s equity framework. Employee stock options and equity compensation received settlement through a combination of cash and CVR-linked distributions, while out-of-the-money options were terminated without compensation.
Public Market Exit
Shares of HOLX have permanently stopped trading. The organization will exit the Nasdaq listing, becoming a completely owned entity within the Blackstone-TPG partnership structure.
On its last trading session, the stock finished at $76.01 — virtually matching its 52-week peak of $76.07, demonstrating how accurately the market anticipated the transaction’s successful conclusion.
Ahead of the closing, six analysts had lowered their earnings projections for future reporting periods. The final analyst recommendation on HOLX stood at Buy with an $83 valuation target.
InvestingPro had rated Hologic with a “GREAT” financial health assessment before the deal’s finalization.
